OWC Pharmaceutical Research Corp. (OTCQB: OWCP), (
Post# of 15624
(Total Views: 189)
Posted On: 08/18/2017 10:50:22 AM
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"
, an Israeli-based developer of cannabinoid-based therapies targeting a variety of medical conditions and disorders, today announced that Ms. Miri Sani has accepted nomination to the Company's Advisory Board.
(Logo: http://mma.prnewswire.com/media/458036/OWC_Logo.jpg )
Ms. Sani, who received an MSc [Master of Science Degree) in Chemistry from the Technion - Israel Institute of Technology, Haifa, Israel, will advise OWC's management on the transition of its innovatively-developed cannabinoid products and delivery systems developed internally and through its hospital relationships, to full industrial and commercial production, in strict compliance with all local and state regulations and protocols, working closely with applicable healthcare agencies and ministries. Ms. Sani will also supervise all manufacturing facilities of third party licensees to assure for quality control in accordance with OWC protocols that were developed at leading hospitals in Israel, for a steady and long-lasting quality of products and measured dosages.
Ms. Sani is the CEO and owner of "Shefa Amirim" Ltd, which provides regulatory affairs and clinical consultation services for early-stage start-ups in various medical fields. Shefa Amirim provides clients with the requisite regulatory plans, designing and conducting the required clinical studies, CRO services and the preparation of technical files and related services necessary for FDA applications and approval. During the past five years, Ms. Sani has shepherded various projects and treatments in the areas of dermatology, proctology, cardio-vascular, ophthalmology, urology, cell therapy, OBYOGN and IVD's through both regulatory affairs and clinical studies.
Mr. Alon Sinai, OWC's Chief Operating Officer commented on Ms. Sani's appointment, stating that "after investing more than two years in research and development of new cannabinoids treatments and delivery systems, we are extremely excited to move into commercial production of our medical cannabis products. Ms. Sani's unique expertise and vast experience supervising such commercialization transitions will facilitate our ability to enjoy a smooth transition while maintaining and following all applicable regulations. We are thrilled to welcome Ms. Sani to our Advisory Board."
More: http://www.pharmiweb.com/pressreleases/pressr...z4q7Pb40bE
, an Israeli-based developer of cannabinoid-based therapies targeting a variety of medical conditions and disorders, today announced that Ms. Miri Sani has accepted nomination to the Company's Advisory Board. (Logo: http://mma.prnewswire.com/media/458036/OWC_Logo.jpg )
Ms. Sani, who received an MSc [Master of Science Degree) in Chemistry from the Technion - Israel Institute of Technology, Haifa, Israel, will advise OWC's management on the transition of its innovatively-developed cannabinoid products and delivery systems developed internally and through its hospital relationships, to full industrial and commercial production, in strict compliance with all local and state regulations and protocols, working closely with applicable healthcare agencies and ministries. Ms. Sani will also supervise all manufacturing facilities of third party licensees to assure for quality control in accordance with OWC protocols that were developed at leading hospitals in Israel, for a steady and long-lasting quality of products and measured dosages.
Ms. Sani is the CEO and owner of "Shefa Amirim" Ltd, which provides regulatory affairs and clinical consultation services for early-stage start-ups in various medical fields. Shefa Amirim provides clients with the requisite regulatory plans, designing and conducting the required clinical studies, CRO services and the preparation of technical files and related services necessary for FDA applications and approval. During the past five years, Ms. Sani has shepherded various projects and treatments in the areas of dermatology, proctology, cardio-vascular, ophthalmology, urology, cell therapy, OBYOGN and IVD's through both regulatory affairs and clinical studies.
Mr. Alon Sinai, OWC's Chief Operating Officer commented on Ms. Sani's appointment, stating that "after investing more than two years in research and development of new cannabinoids treatments and delivery systems, we are extremely excited to move into commercial production of our medical cannabis products. Ms. Sani's unique expertise and vast experience supervising such commercialization transitions will facilitate our ability to enjoy a smooth transition while maintaining and following all applicable regulations. We are thrilled to welcome Ms. Sani to our Advisory Board."
More: http://www.pharmiweb.com/pressreleases/pressr...z4q7Pb40bE
(0)
(0)